A Transformative Biomarker for Alzheimer's Disease

Discover the power of pTau217, the leading diagnostic biomarker for Alzheimer's disease. Unlock the potential of this commercially available assay and join the fight against Alzheimer's today.

The ALZpath pTau217 Assay

The ALZpath pTau217 research use only (RUO) assay utilizes exclusive proprietary antibodies for enhanced precision and reliability on the single molecule array (Simoa®) platform. The ALZpath pTau217 Assay enables researchers to measure pTau217 levels reliably, opening doors to groundbreaking advancements in Alzheimer’s research.

Highly Sensitive Assay: Analytical lower limit of quantification (LLOQ): 0.02 pg/mL; limit of detection (LOD): 0.0052-0.0074 pg/mL

Matrix: Plasma and cerebrospinal fluid (CSF)

Testing Options: Provide samples for analysis or receive assay kits for analysis in your laboratory

How to order ALZpath pTau217 Assay

We have enhanced the manufacturing and distribution of our assay by partnering with Quanterix. Contact us to start an order for
assay kits or sample analysis.

Exploring Applications of the ALZpath pTau217 Assay:
Insights from Research Studies

Sleep Quality and pTau217

Ashley Price et al.
University of Rhode Island

Price et al. explored the relationship between sleep quality and pTau217 in older adults with mild cognitive impairment (MCI) and mild Alzheimer's Disease (AD). They found that poorer sleep quality correlated with increased pTau217 levels, suggesting a link between sleep and tau pathology.

Learn More

pTau217 as an Early Plasma Marker for Alzheimer's Dementia

Luca Kleineida et al.
German Center for Neurodegenerative Diseases 

Kleineida et al. investigated the capacity for pTau217 to predict Alzheimer's dementia in older primary care patients. Their findings demonstrated that elevated pTau217 is strongly associated with conversion to Alzheimer's dementia up to eight years later, surpassing the performance of other biomarkers for AD.

Learn More

Detection of pTau217 in Tear Fluid

Guglielmo Di Molfetta et al.
University of Gothenburg

Di Molfetta et al. detected pTau217 in tear fluid, highlighting the potential of tear fluid as a non-invasive biofluid for biomarker assessment in neurodegenerative disorders.

Learn More

Our Partnerships

Join our global network of partners and integrate the state-of-the-art ALZpath pTau217 assay
into your research or diagnostic efforts for Alzheimer’s disease

62.9K Samples

12 Countries

60+ Collaborators

Interested in partnering with ALZpath? Please contact us below.

Order Now

"*" indicates required fields

Kit or Sample Analysis*
This field is for validation purposes and should be left unchanged.